Asked by: Scott Arthur (Labour - Edinburgh South West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the annual cost to the NHS of treating breast cancer cases in the UK that are attributable to alcohol consumption.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government and the National Health Service recognise that a healthy lifestyle can help reduce the biggest risk factors of certain cancers. The Government welcomes the recent publication of the World Cancer Research Fund's 2025 report.
The UK Chief Medical Officers’ low-risk drinking guidelines and the NHS webpage on the risks of alcohol, clearly state that alcohol consumption can increase the risk of developing seven types of cancer, including breast cancer.
The National Disease Registration Service (NDRS) collects patient data on cancer, congenital anomalies and rare diseases. The NDRS does not collect data on the causes of cancer. Therefore, the Department has not made a formal assessment on the annual cost to the NHS of treating breast cancer cases in the United Kingdom that are attributable to alcohol consumption.
The National Cancer Plan for England, which will be published in the new year, will build on the shift from sickness to prevention set out by the 10-Year Health Plan and will seek to reduce risk factors. The plan will cover the entirety of the cancer pathway, from referral and diagnosis to treatment and ongoing care, as well as prevention. This will include alcohol consumption, alongside other risk factors, given alcohol is linked to an increased risk of seven types of cancer, including breast cancer.
Asked by: Ruth Jones (Labour - Newport West and Islwyn)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when NHS England will publish the breast screening uptake improvement plan.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
In 2026, NHS England is planning to publish a Breast Screening Programme Uptake Improvement Review to help improve uptake and address inequalities.
They aim to publish a review of actions taken at a national level by the NHS Breast Screening Programme so far, as well as setting out where the focus will be going forward, to support local services to drive uptake even further.
Asked by: Al Pinkerton (Liberal Democrat - Surrey Heath)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the potential impact of stilbestrol on women.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Medicine and Healthcare products Regulatory Agency continuously assesses the benefit and risk balance of all medicines, at the time of initial licensing and throughout their use in clinical practice, carefully evaluating any emerging evidence on their benefits and risks.
In 1971, a United States study identified that diethylstilbestrol (DES) could cause a distinct type of cancer in the daughters of women who took DES in early pregnancy. It was subsequently contraindicated in pregnancy, pre-menopausal women, children, and young adults. The issue of DES and vaginal carcinoma in the daughters of women who took DES in pregnancy was reviewed by the predecessor to Commission on Human Medicines, the Committee on Safety of Medicines (CSM) in the early 1970s. In 1973, CSM wrote to all doctors to inform them of the results of the US study and the absence of identified cases in the United Kingdom.
A small increased risk of breast cancer in women who received DES whilst pregnant was first identified in the 1980s and confirmed in further studies in the 1990s, when a longer follow up of women who had taken DES was available. No increased risk of other cancers has been established, including endometrial cancer or ovarian cancer.
Since 1992, the National Cancer Institute at the US National Institutes of Health has been conducting the DES Follow-up Study of more than 21,000 mothers, daughters, and sons exposed in the womb during the mother’s pregnancy, to better understand the long-term health effects of exposure to DES. The findings of this follow up have been published in scientific literature.
Daughters of individuals exposed to DES are at increased risk of clear cell cancer of the cervix and vagina. The current advice from the NHS England is that routine cervical screening is appropriate for those who believed they were exposed to DES in utero.
Participation in the National Breast Screening Programme is also recommended. Pregnant women who know that they were exposed in utero to DES should inform their obstetrician and be aware of the increased risks of ectopic pregnancy and preterm labour.
Asked by: Ruth Jones (Labour - Newport West and Islwyn)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with Welsh Government counterparts about sharing best practice around increasing screening uptake for breast cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The UK National Screening Committee (UK NSC) advises ministers and the National Health Service in the four nations of the United Kingdom about all aspects of screening. The implementation of any UK NSC screening recommendation is a devolved matter.
Asked by: Sarah Owen (Labour - Luton North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many reports of BIA-ALCL there have been in the UK; and which manufacturers of breast implants those reports have been associated with.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
As has been previously shared in evidence submitted to the Women and Equalities Select Committee in July 2025, with further information in the document attached, the Medicines and Healthcare product Regulatory Agency (MHRA) closely monitors Breast Implant Associated- Anaplastic Large Cell Lymphoma (BIA-ALCL), a cancer of the immune system, not a breast cancer, and publishes the output from this monitoring on the GOV.UK webpage, at the following link:
https://www.gov.uk/guidance/breast-implants-and-anaplastic-large-cell-lymphoma-alcl
The MHRA has developed, with advice from independent expert advisory group, a follow up strategy to collect further data on adverse incidents reporting BIA-ALCL. This has informed the information that is published on the MHRA webpage relating to BIA-ALCL which includes the most up to date number of confirmed reports of BIA-ALCL made to the MHRA, and the breakdown of the number of confirmed reports of primary BIA-ALCL cases by manufacturer of breast implant.
Please note that the data on the GOV.UK webpage should be interpreted in the context of the ‘Notes and limitations to the data’ section also provided on the webpage.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential merits of increasing the accessibility of Enhertu as a treatment for breast cancer.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Decisions on whether new medicines should be routinely funded by the National Health Service in England are made on the basis of recommendations from the National Institute for Health and Care Excellence (NICE) following an evaluation of a treatment’s costs and benefits. These are very difficult decisions to make, and it is important that they are made independently and on the basis of the available evidence.
NICE has recommended Enhertu (trastuzumab deruxtecan) in advanced breast cancer for treating HER2-positive unresectable or metastatic breast cancer after one or more anti-HER 2 treatments and for treating HER2-positive unresectable or metastatic breast cancer after two or more anti-HER2 therapies. Enhertu is now funded for eligible patients in England in line with NICE’s recommendations.
NICE published guidance in July 2024 on the use of Enhertu for the treatment of HER-2 low metastatic and unresectable breast cancer and was unfortunately unable to recommend it for routine NHS funding. I understand that NICE and NHS England sought to apply as much flexibility as they can in their considerations of Enhertu for HER2-low breast cancer and have made it clear to the companies that their pricing of the drug remains the only obstacle to access.
Ministers met with the manufacturers of Enhertu, AstraZeneca, and Daiichi Sankyo in November 2024, to encourage them to re-engage in commercial discussions with NHS England. Despite NICE and NHS England offering unprecedented flexibilities, the companies were unable to offer Enhertu at a cost-effective price. NICE’s guidance published in July 2024 will therefore remain unchanged. Although the deadline for a rapid review has now passed, NICE has reassured me that the door remains open for the companies to enter into a new NICE appraisal if they are willing to offer Enhertu at a cost-effective price.
Asked by: Helen Maguire (Liberal Democrat - Epsom and Ewell)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of trends in the level of survival rates for bladder cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Improving cancer outcomes, including for bladder cancer, is a priority for the Government. The forthcoming National Cancer Plan will set out further actions to improve earlier diagnosis, expand access to the latest treatments and technologies, and improve survival rates across England.
National cancer registry data shows a small but sustained decline in bladder cancer survival rates over recent years. One-year survival fell from approximately 72% to 69.6%, and five-year survival from 51.5% to 47.2% between 2007 to 2011 and 2016 to 2020.
To improve treatment times, we have invested £70 million of funding into new radiotherapy treatment machines to replace older, less efficient machines. These new machines are currently being rolled out to trusts throughout the country. These newer machines will reduce treatment times, boost productivity, and allow more patients to be seen over the same period.
In addition, non-specific symptom pathways have been introduced to speed up diagnosis for patients whose symptoms may indicate cancer but which do not align clearly with a specific tumour type. This helps ensure that more patients are referred, investigated, and diagnosed earlier, including cases of bladder cancer that present with broader or less specific symptoms.
The NHS Cancer Programme has commissioned 10 national clinical audits covering breast, ovarian, pancreatic, lung, prostate, oesophago-gastric, bowel, non-Hodgkin lymphoma, and kidney cancers. These were selected as auditing was expected to have the greatest impact on reducing unwarranted variation in care. For this reason, there are currently no plans to undertake a national clinical audit for bladder cancer, though bladder cancer outcomes continue to be monitored through existing national cancer datasets.
Asked by: Helen Maguire (Liberal Democrat - Epsom and Ewell)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of undertaking a National Bladder Cancer Audit.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Improving cancer outcomes, including for bladder cancer, is a priority for the Government. The forthcoming National Cancer Plan will set out further actions to improve earlier diagnosis, expand access to the latest treatments and technologies, and improve survival rates across England.
National cancer registry data shows a small but sustained decline in bladder cancer survival rates over recent years. One-year survival fell from approximately 72% to 69.6%, and five-year survival from 51.5% to 47.2% between 2007 to 2011 and 2016 to 2020.
To improve treatment times, we have invested £70 million of funding into new radiotherapy treatment machines to replace older, less efficient machines. These new machines are currently being rolled out to trusts throughout the country. These newer machines will reduce treatment times, boost productivity, and allow more patients to be seen over the same period.
In addition, non-specific symptom pathways have been introduced to speed up diagnosis for patients whose symptoms may indicate cancer but which do not align clearly with a specific tumour type. This helps ensure that more patients are referred, investigated, and diagnosed earlier, including cases of bladder cancer that present with broader or less specific symptoms.
The NHS Cancer Programme has commissioned 10 national clinical audits covering breast, ovarian, pancreatic, lung, prostate, oesophago-gastric, bowel, non-Hodgkin lymphoma, and kidney cancers. These were selected as auditing was expected to have the greatest impact on reducing unwarranted variation in care. For this reason, there are currently no plans to undertake a national clinical audit for bladder cancer, though bladder cancer outcomes continue to be monitored through existing national cancer datasets.
Asked by: Helen Maguire (Liberal Democrat - Epsom and Ewell)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase survival rates for bladder cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Improving cancer outcomes, including for bladder cancer, is a priority for the Government. The forthcoming National Cancer Plan will set out further actions to improve earlier diagnosis, expand access to the latest treatments and technologies, and improve survival rates across England.
National cancer registry data shows a small but sustained decline in bladder cancer survival rates over recent years. One-year survival fell from approximately 72% to 69.6%, and five-year survival from 51.5% to 47.2% between 2007 to 2011 and 2016 to 2020.
To improve treatment times, we have invested £70 million of funding into new radiotherapy treatment machines to replace older, less efficient machines. These new machines are currently being rolled out to trusts throughout the country. These newer machines will reduce treatment times, boost productivity, and allow more patients to be seen over the same period.
In addition, non-specific symptom pathways have been introduced to speed up diagnosis for patients whose symptoms may indicate cancer but which do not align clearly with a specific tumour type. This helps ensure that more patients are referred, investigated, and diagnosed earlier, including cases of bladder cancer that present with broader or less specific symptoms.
The NHS Cancer Programme has commissioned 10 national clinical audits covering breast, ovarian, pancreatic, lung, prostate, oesophago-gastric, bowel, non-Hodgkin lymphoma, and kidney cancers. These were selected as auditing was expected to have the greatest impact on reducing unwarranted variation in care. For this reason, there are currently no plans to undertake a national clinical audit for bladder cancer, though bladder cancer outcomes continue to be monitored through existing national cancer datasets.
Asked by: Carla Lockhart (Democratic Unionist Party - Upper Bann)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, what assessment she has made of the potential impact of AI technologies on early cancer detection.
Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
The Department for Science, Innovation and Technology invests in cancer research via UK Research and Innovation (UKRI), and the Department of Health and Social Care via the National Institute for Health and Care Research (NIHR). UKRI and NIHR support research which explores the impact of AI on cancer diagnosis, including the NIHR £11 million Edith trial (using AI to assist radiologists in breast cancer screening). AI presents significant opportunities for improving outcomes and diagnosis for cancer patients and driving faster triage of patients with suspected symptoms. Evaluations of the impact of AI on cancer diagnosis are ongoing.